Drug news
NICE recommends Entyvio as a treatment for Ulcerative Colitis- Takeda
The National Institute for Health and Care Excellence (NICE) now recommends Entyvio (vedolizumab) from Takeda,as a maintenance therapy for adults with moderate to severe Ulcerative Colitis where they cannot tolerate TNF Alpha inhibitors. A final decision from NICE is due in April 2015.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins